Emerald Acquisition’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Emerald Acquisition’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$2.04M	Sell	30,767 -3,338	-10%	-$206K	﹤0.01%	1739
2016 Q2	$1.84M	Buy	+34,105	New	+$1.87M	﹤0.01%	1871

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Emerald Acquisition's XBI Position: Q3 2016 in Review

Emerald Acquisition reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 9.8% in Q3 2016, selling an estimated $206K and leaving 30,767 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1739.

Emerald Acquisition first reported a position in XBI in Q2 2016 and has held it in 2 quarters since. 227 funds tracked by Wall St. Rank hold XBI as of Q3 2016.

Emerald Acquisition held 30,767 shares of State Street SPDR S&P Biotech ETF worth $2.04M as of Q3 2016.
Emerald Acquisition sold 3,338 State Street SPDR S&P Biotech ETF shares in Q3 2016, an estimated $206K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1739 holding.
Emerald Acquisition first reported a position in State Street SPDR S&P Biotech ETF in Q2 2016 and has held it in 2 quarters since.
227 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.